Zacks Investment Research upgraded shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) from a hold rating to a buy rating in a research note issued to investors on Wednesday. Zacks Investment Research currently has $37.00 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “
Several other equities analysts also recently commented on the company. BidaskClub upgraded Assembly Biosciences from a buy rating to a strong-buy rating in a research report on Thursday, August 24th. Chardan Capital restated a buy rating on shares of Assembly Biosciences in a research report on Sunday, September 17th. Finally, Jefferies Group LLC initiated coverage on Assembly Biosciences in a research report on Wednesday, November 8th. They set a buy rating and a $50.00 target price for the company.
Assembly Biosciences (ASMB) traded up $0.59 during trading on Wednesday, hitting $35.54. The company had a trading volume of 100,902 shares, compared to its average volume of 112,811. Assembly Biosciences has a 1-year low of $11.07 and a 1-year high of $36.90.
In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $29.55, for a total value of $29,550.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 19.60% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. Nationwide Fund Advisors bought a new position in Assembly Biosciences in the 2nd quarter valued at $161,000. Parametric Portfolio Associates LLC bought a new position in Assembly Biosciences in the 1st quarter valued at $226,000. Renaissance Technologies LLC bought a new position in Assembly Biosciences in the 1st quarter valued at $242,000. Legal & General Group Plc bought a new position in Assembly Biosciences in the 2nd quarter valued at $212,000. Finally, Wells Fargo & Company MN bought a new position in Assembly Biosciences in the 2nd quarter valued at $213,000. Hedge funds and other institutional investors own 62.19% of the company’s stock.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.